InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
03 févr. 2021 08h32 HE
|
InspireMD
TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid...
InspireMD Announces Third Quarter 2020 Financial Results
09 nov. 2020 06h30 HE
|
InspireMD
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET TEL AVIV,...
InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors
13 oct. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
10 sept. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
10 août 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Second Quarter 2020 Financial Results
05 août 2020 06h40 HE
|
InspireMD
In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating...